313 related articles for article (PubMed ID: 25516478)
21. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition.
Mao W; Ghasemzadeh A; Freeman ZT; Obradovic A; Chaimowitz MG; Nirschl TR; McKiernan E; Yegnasubramanian S; Drake CG
J Immunother Cancer; 2019 Oct; 7(1):277. PubMed ID: 31653272
[TBL] [Abstract][Full Text] [Related]
23. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8
Fehlings M; Simoni Y; Penny HL; Becht E; Loh CY; Gubin MM; Ward JP; Wong SC; Schreiber RD; Newell EW
Nat Commun; 2017 Sep; 8(1):562. PubMed ID: 28916749
[TBL] [Abstract][Full Text] [Related]
24. Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes.
Klevorn LE; Berrien-Elliott MM; Yuan J; Kuehm LM; Felock GD; Crowe SA; Teague RM
Cancer Immunol Res; 2016 Dec; 4(12):1016-1026. PubMed ID: 27803062
[TBL] [Abstract][Full Text] [Related]
25. Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment.
Arina A; Corrales L; Bronte V
Semin Immunol; 2016 Feb; 28(1):54-63. PubMed ID: 26872631
[TBL] [Abstract][Full Text] [Related]
26. CD96 Is an Immune Checkpoint That Regulates CD8
Mittal D; Lepletier A; Madore J; Aguilera AR; Stannard K; Blake SJ; Whitehall VLJ; Liu C; Bettington ML; Takeda K; Long GV; Scolyer RA; Lan R; Siemers N; Korman A; Teng MWL; Johnston RJ; Dougall WC; Smyth MJ
Cancer Immunol Res; 2019 Apr; 7(4):559-571. PubMed ID: 30894377
[TBL] [Abstract][Full Text] [Related]
27. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
[TBL] [Abstract][Full Text] [Related]
28. Infection history determines the differentiation state of human CD8+ T cells.
van Aalderen MC; Remmerswaal EB; Verstegen NJ; Hombrink P; ten Brinke A; Pircher H; Kootstra NA; ten Berge IJ; van Lier RA
J Virol; 2015 May; 89(9):5110-23. PubMed ID: 25717102
[TBL] [Abstract][Full Text] [Related]
29. Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy.
Sckisel GD; Mirsoian A; Bouchlaka MN; Tietze JK; Chen M; Blazar BR; Murphy WJ
Cancer Immunol Immunother; 2015 Dec; 64(12):1541-52. PubMed ID: 26423422
[TBL] [Abstract][Full Text] [Related]
30. Inflammation programs self-reactive CD8+ T cells to acquire T-box-mediated effector function but does not prevent deletional tolerance.
Jackson SR; Yuan J; Berrien-Elliott MM; Chen CL; Meyer JM; Donlin MJ; Teague RM
J Leukoc Biol; 2014 Sep; 96(3):397-410. PubMed ID: 24823810
[TBL] [Abstract][Full Text] [Related]
31. Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8
Redmond WL; Linch SN
Hum Vaccin Immunother; 2016 Oct; 12(10):2519-2522. PubMed ID: 27459422
[TBL] [Abstract][Full Text] [Related]
32. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
[TBL] [Abstract][Full Text] [Related]
33. Mitochondrial arginase-2 is a cell‑autonomous regulator of CD8+ T cell function and antitumor efficacy.
Martí i Líndez AA; Dunand-Sauthier I; Conti M; Gobet F; Núñez N; Hannich JT; Riezman H; Geiger R; Piersigilli A; Hahn K; Lemeille S; Becher B; De Smedt T; Hugues S; Reith W
JCI Insight; 2019 Nov; 4(24):. PubMed ID: 31751318
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
35. Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1.
Leclerc M; Voilin E; Gros G; Corgnac S; de Montpréville V; Validire P; Bismuth G; Mami-Chouaib F
Nat Commun; 2019 Jul; 10(1):3345. PubMed ID: 31350404
[TBL] [Abstract][Full Text] [Related]
36. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
[TBL] [Abstract][Full Text] [Related]
37. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
38. Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.
Anichini A; Molla A; Vegetti C; Bersani I; Zappasodi R; Arienti F; Ravagnani F; Maurichi A; Patuzzo R; Santinami M; Pircher H; Di Nicola M; Mortarini R
Cancer Res; 2010 Nov; 70(21):8378-87. PubMed ID: 20861189
[TBL] [Abstract][Full Text] [Related]
39. CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin.
Hegel JK; Knieke K; Kolar P; Reiner SL; Brunner-Weinzierl MC
Eur J Immunol; 2009 Mar; 39(3):883-93. PubMed ID: 19224637
[TBL] [Abstract][Full Text] [Related]
40. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells.
Chang LY; Lin YC; Mahalingam J; Huang CT; Chen TW; Kang CW; Peng HM; Chu YY; Chiang JM; Dutta A; Day YJ; Chen TC; Yeh CT; Lin CY
Cancer Res; 2012 Mar; 72(5):1092-102. PubMed ID: 22282655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
